Physician profile
Sara A Ramirez
NPI 1467401638
$3,226.95
in general payments reported to CMS, 2019-2025
29 companies · $597 in 2025
The $597 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $266 · 2021: $391 · 2022: $421 · 2023: $561 · 2024: $189 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.78 | 2019-2023 | |
| Pfizer INC. | $270.75 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $253.42 | 2019-2025 | |
| Siemens Medical Solutions USA, INC. | $214.48 | 2023-2025 | Embozene, Microthermx Microwave Ablation System, Oncozene |
| Therapeuticsmd, INC. | $211.24 | 2019-2022 | |
| Aspira Women'S Health INC | $196.23 | 2022-2024 | Ova1 |
| Lupin INC. | $158.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $143.75 | 2025 | Spravato |
| Exeltis, USA INC. | $132.00 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $124.91 | 2019-2023 | Veozah |
| Biogen, INC. | $112.93 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $94.15 | 2019-2023 | Aptima |
| Shield Therapeutics INC | $85.73 | 2022-2023 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $79.40 | 2019-2025 | |
| Organon LLC | $72.82 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $58.94 | 2023-2025 | Myfembree |
| Roche Diagnostics Corporation | $56.24 | 2019-2021 | |
| Novo Nordisk INC | $43.28 | 2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $36.98 | 2019-2020 | |
| Daiichi Sankyo INC. | $34.82 | 2019-2020 | |
| Mycovia Pharmaceuticals, INC. | $33.36 | 2022-2023 | Vivjoa |
| Allergan, INC. | $28.83 | 2019 | |
| Minerva Surgical, INC | $23.48 | 2023 | |
| Exact Sciences Corporation | $18.62 | 2025 | Cologuard Collection Kit |
| Coopersurgical, INC. | $15.25 | 2019 | |
| Evofem Biosciences, INC. | $14.02 | 2022 | |
| Myovant Sciences INC. | $13.85 | 2021 | |
| Avion Pharmaceuticals | $12.82 | 2020 | |
| Ethicon US, LLC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.